TYBOST

Cobicistat 150mg, Oral tablet

Cannabis

· Severity: Major

· Notes for Consumers: Discuss cannabis use with your care team. The effects of cannabis may be altered if used with your medication. Call emergency services right away if you experience slow or shallow breathing, shortness of breath, feeling faint, dizziness, confusion, or trouble staying awake.

· Notes for Professionals: Advise patients to avoid cannabis use during cobicistat treatment. Concomitant use may alter the exposure of some cannabinoids and increase the risk for adverse reactions. The cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are CYP3A substrates and cobicistat is a strong CYP3A inhibitor. Concomitant use of a cannabinoid product containing THC and CBD at an approximate 1:1 ratio with another strong CYP3A inhibitor increased THC, 11-OH-THC, and CBD peak exposures by 1.3-, 3-, and 1.9-fold respectively.

Cobicistat 150mg, Oral tablet

Grapefruit juice

· Severity: Moderate

· Notes for Consumers: Although an interaction is possible, these drugs can be used together with caution. You may experience more side effects. Report any new or unusual side effects to your health care professional.

· Notes for Professionals: Caution is warranted when cobicistat is administered with grapefruit juice as there is a potential for elevated cobicistat concentrations. Grapefruit juice is a CYP3A4 and CYP2D6 inhibitor, while cobicistat is a substrate of CYP3A4 and CYP2D6.

<b>DISCLAIMER:</b><em> This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.</em>